Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

Summary

Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease characterized by pathogenic autoantibodies production against nuclear structures . SLE affecting mainly women of childbearing age and is characterized by unpredictable flares and remissions. Disease severity varied from a mild episodic disorder to a rapidly progressive life-threatening illness. The kidney is the most commonly involved visceral organ in SLE. Therefore, identifying new noninvasive biomarkers of LN severity and outcome is mandatory. IL-17 is a potent pro-infammatory cytokine that amplifes T-cell activation and stimulates fibroblast cells, endothelial, and epithelial cells to produce several pro-infammatory mediators, including IL-1β, IL-6, and TNF-α. IL-17 receptor signaling enhances the expression of multiple pro-infammatory mediators. Hence, IL-17 enhances the production of neutrophil-attracting chemokines

Eligibility

Inclusion Criteria:

* ● Aged ≥18 years.

  * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
  * Patients cooperative and can answer questions.
  * Patients who are able and willing to give written informed consent

Exclusion Criteria:

* ● Individuals with other autoimmune diseases.

  * Patients receive any hyperuricemia treatment
  * Pregnancy
  * Malignancy
  * Diabetes.
  * Hypertension.
  * Heart failure.
  * Hepatic diseases.
  * Chronic renal failure other than lupus nephritis.
  * Renal artery stenosis.
  * Renal vein thrombosis.
  * Intrarenal arteriovenous fistula.
  * Obstructive nephropathy.
  * Urinary tract obstruction that could affect RI of intra renal arteries.
  * Uncooperative patients.
  * Patients not able and willing to give written informed consent.

Conditions2

Browse More Trials